Aurobindo Pharma Q2 Results Review - Several Growth Levers In Place To Drive Topline: Axis Securities

"BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BQ Prime’s subscribers an opportunity to expand their understanding of companies, sectors and the economy..Axis Securities Report.Aurobindo Pharma Ltd.'s profit after tax stood above our estimates by 14%. Aurobindo Pharma’s consolidated revenue grew by 25.8% YoY and gross margins improved by 122 basis points QoQ. Ebitda margins improved by 222 bps QoQ. The U.S. revenue at $ 409 million was up 7.1% QoQ. Injectable businesses in the U.S. reported 2.5% QoQ growth, driven by strong underlying business growth as price erosion was negligible during the last quarter. Oral and over the counter business has driven growth in the U.S. by 7.2% and 12.3% QoQ respectively..While European business de-grew by 3.7% QoQ, the growth markets grew by 16% QoQ. Antiretroviral drug optimisation sales increased by 31.6% QoQ to Rs 190 crore. Active pharmaceutical ingredient sales were up 12.98% QoQ at Rs 1,166 crore..Outlook: Aurobindo Pharma has a number of levers to grow its topline:Generic injectibles, Eugia ($ 520 million sales) may grow by low double-digit growth based on value-added approval, The launch of Trastzumab biosimilars in H2 FY24E, The launch of Pen–G injectible in Q1 FY25E and One time opportunity in gRevlimid in the next 2-3 years. The base business – oral solids could grow to low single-digit growth based on the launch of 40 new products.Ebitda margins could be in the range of ~ 18%-20% due to changes in product mix and fall in raw material costs. Therefore, we recommend a 'Buy' on the stock..Key risks to our estimates and target price- The U.S. Food and Drug Administration inspection and issuing of warning letter/official action indicated or 483 observations may impact the revenue growth.  Entry of new players may increase pricing pressure in the injectable portfolio. Delay in launching biosimilars in the market..Click on the attachment to read the full report:.Heidelberg Cement Q2 Results Review - Poor Quarter; Near Term Expansion Missing: Dolat Capital.DISCLAIMERThis report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime..Users have no license to copy, modify, or distribute the content without permission of the Original Owner."

Aurobindo Pharma Q2 Results Review - Several Growth Levers In Place To Drive Topline: Axis Securities

Aurobindo Pharma’s European business grew by 10.7% QoQ while the growth markets de-grew by 17.8% QoQ.

NDTV Profit

NDTV Profit

Follow Us

DOWNLOAD THE APP

Aurobindo Pharma Q2 Results Review - Several Growth Levers In Place To Drive Topline: Axis Securities

Aurobindo Pharma’s European business grew by 10.7% QoQ while the growth markets de-grew by 17.8% QoQ.

Choose a plan

Follow Us

DOWNLOAD THE APP